JOP20240241A1 - حمض نووي مُحسَّن بالكودون يشفر بروتين fviii-bdd - Google Patents

حمض نووي مُحسَّن بالكودون يشفر بروتين fviii-bdd

Info

Publication number
JOP20240241A1
JOP20240241A1 JOJO/P/2024/0241A JOP20240241A JOP20240241A1 JO P20240241 A1 JOP20240241 A1 JO P20240241A1 JO P20240241 A JOP20240241 A JO P20240241A JO P20240241 A1 JOP20240241 A1 JO P20240241A1
Authority
JO
Jordan
Prior art keywords
codon
dna encoding
enhanced dna
bdd
fviii
Prior art date
Application number
JOJO/P/2024/0241A
Other languages
Arabic (ar)
English (en)
Inventor
Mariya Pavlovna Perepelkina
Anna Nikolaevna Strelkova
Pavel Mikhailovich Gershovich
Tatiana Evgenievna Shugaeva
Pavel Andreevich Iakovlev
Elena Veniaminovna Vlasova
Anastasiia Vladimirovna Fomina
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2022111734A external-priority patent/RU2808564C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of JOP20240241A1 publication Critical patent/JOP20240241A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JOJO/P/2024/0241A 2022-04-28 2024-10-27 حمض نووي مُحسَّن بالكودون يشفر بروتين fviii-bdd JOP20240241A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2022111734A RU2808564C2 (ru) 2022-04-28 Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови VIII c делетированным B доменом, и ее применение
PCT/RU2023/050094 WO2023211316A1 (en) 2022-04-28 2023-04-18 Codon-optimized nucleic acid encoding the fviii-bdd

Publications (1)

Publication Number Publication Date
JOP20240241A1 true JOP20240241A1 (ar) 2024-10-27

Family

ID=88482201

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0241A JOP20240241A1 (ar) 2022-04-28 2024-10-27 حمض نووي مُحسَّن بالكودون يشفر بروتين fviii-bdd

Country Status (20)

Country Link
US (1) US20250282847A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514836A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025514313A (cg-RX-API-DMAC7.html)
KR (1) KR20250007615A (cg-RX-API-DMAC7.html)
CN (1) CN116970629A (cg-RX-API-DMAC7.html)
AR (1) AR129163A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023261338A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250665A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003296A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024014690A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240524A (cg-RX-API-DMAC7.html)
IL (1) IL316584A (cg-RX-API-DMAC7.html)
JO (1) JOP20240241A1 (cg-RX-API-DMAC7.html)
MA (1) MA68586A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013280A (cg-RX-API-DMAC7.html)
PE (1) PE20251838A1 (cg-RX-API-DMAC7.html)
PY (1) PY2331315A (cg-RX-API-DMAC7.html)
TW (1) TW202346601A (cg-RX-API-DMAC7.html)
UY (1) UY40241A (cg-RX-API-DMAC7.html)
WO (1) WO2023211316A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
CN108884145B (zh) * 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
CN113226352B (zh) * 2018-08-24 2025-08-26 星火治疗有限公司 最优化启动子序列、无内含子的表达结构及使用方法

Also Published As

Publication number Publication date
US20250282847A1 (en) 2025-09-11
KR20250007615A (ko) 2025-01-14
CR20240524A (es) 2025-05-05
JP2025514313A (ja) 2025-05-02
UY40241A (es) 2023-10-13
CL2024003296A1 (es) 2025-02-21
WO2023211316A1 (en) 2023-11-02
MA68586A1 (fr) 2025-04-30
CA3250665A1 (en) 2023-11-02
EP4514836A1 (en) 2025-03-05
IL316584A (en) 2024-12-01
PE20251838A1 (es) 2025-07-17
CN116970629A (zh) 2023-10-31
AU2023261338A1 (en) 2024-11-21
CO2024014690A2 (es) 2025-03-06
AR129163A1 (es) 2024-07-24
TW202346601A (zh) 2023-12-01
MX2024013280A (es) 2024-12-06
PY2331315A (es) 2023-10-31

Similar Documents

Publication Publication Date Title
CL2021002739A1 (es) Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
PH12017502281A1 (en) Thermostable cas9 nucleases
EA202090034A1 (ru) Способы модификации сплайсинга рнк
JOP20230168A1 (ar) التأثير التآزري لـ SMN1 و miR-23a في علاج ضمور العضلات النخاعي
ES2177475T1 (es) Genes de corynebacterium glutamicum que codifican proteinas de una ruta metabolica.
MX2019002345A (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
DK0941318T3 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
DE60045191D1 (de) Corynebacterium glutamicum gene, die für stoffwechselproteine kodieren
CY1120789T1 (el) Προϊοντα γονιδιων εκφραζομενα διαφορικα μεσα σε ογκους και εφαρμογη αυτων
SG10201903381TA (en) Artificial nucleic acid molecules
SG10201906673WA (en) Artificial nucleic acid molecules
AU2002327412A1 (en) Methods and compositions relating to improved lentiviral vector production systems
ZA202104912B (en) Rna encoding a protein
WO2022046935A3 (en) Methods and compositions for treating glioblastoma
KR100469936B1 (ko) 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
JOP20220327A1 (ar) حمض نووي معزز بالكودون يشفَر بروتين smn1
MX2022015802A (es) Construcciones de anellovirus en tandem.
JOP20240240A1 (ar) حمض نووي معزول يشفر بروتين اندماج قائم على fviii-bdd وعلى ببتيد إشارة غير متجانس
ATE532861T1 (de) Expressionsvektor
PH12021550563A1 (en) Pacas9 nuclease
DK2066790T3 (da) Galactosyltransferase
MX2024013280A (es) Acido nucleico de codon optimizado que codifica la proteina del factor viii de coagulacion de dominio b suprimido, y uso del mismo
GEAP202416228A (en) Method of producing a recombinant protein in a host cell which has a disabled rhamnose metabolism as well as expression vectors, host cells and recombinant proteins thereof
JOP20230208A1 (ar) حمض نووي مُحسّن بالكودون يشفر بروتين fix
JOP20240270A1 (ar) حمض نووي له نشاط مُروِّج واستخداماته